
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is positioned for continued growth with a diverse portfolio of oncology therapeutics, strong financial performance, and a robust pipeline of drugs in clinical trials. The company's successful commercialization of Brukinsa and promising developments in their other drugs, as well as their strategic partnerships with AbbVie and AstraZeneca, demonstrate their potential for success in a competitive market. However, potential setbacks and competition should also be considered when evaluating the company's long-term outlook.
Bears say
BeOne Medicines is facing potential R&D, regulatory, and commercial risks, as well as competition from established players in the oncology market. While the company's main revenue driver, Brukinsa, has shown promising results in clinical trials, there is the potential for slower sales than expected. However, with a strong pipeline of over 50 drugs in development, BeOne has opportunities for future growth and market expansion.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares